2023
DOI: 10.1016/j.jddst.2023.104193
|View full text |Cite
|
Sign up to set email alerts
|

Nanotheranostic: The futuristic therapy for copper mediated neurological sequelae

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(6 citation statements)
references
References 128 publications
0
6
0
Order By: Relevance
“…As a result, both the copper uptake mechanisms of transporter and reductase can regulate intracellular copper levels in cancer cells [113]. Despite the fact that CTR1, ATOX1, ATP7A, and ATP7B are involved in cisplatin transportation, as previously stated, they are also involved in copper uptake, distribution, and efflux in cancer [76]. According to some proteomic studies, high expression of ATP7A and ATOX1 is associated with poor survival [79,114].…”
Section: Copper and Zinc In Chelating Structuresmentioning
confidence: 98%
See 2 more Smart Citations
“…As a result, both the copper uptake mechanisms of transporter and reductase can regulate intracellular copper levels in cancer cells [113]. Despite the fact that CTR1, ATOX1, ATP7A, and ATP7B are involved in cisplatin transportation, as previously stated, they are also involved in copper uptake, distribution, and efflux in cancer [76]. According to some proteomic studies, high expression of ATP7A and ATOX1 is associated with poor survival [79,114].…”
Section: Copper and Zinc In Chelating Structuresmentioning
confidence: 98%
“…Because of the urine and biliary excretions, the outcomes of this therapy are low toxicity, fewer side effects, and easy diagnosis [73,75]. As a result, this chelator modulates homeostasis by regulating the expression of high-affinity copper uptake protein (CTR)-1 [76]. Thus, this causes the cisplatin chemoresistance to be removed by the invasive tumours that actively consume copper delivery in ATPase7A and ATPase7B to release the oncogenic enzymes and increase therapeutic efficacy [77].…”
Section: Copper and Zinc For Anti-chemoresistance In Osteosarcoma The...mentioning
confidence: 99%
See 1 more Smart Citation
“…Due to the urine and biliary excretions, the outcomes of this therapy are low toxicity, fewer side effects, and easy diagnosis [ 70 , 72 ]. As a result, this chelator modulates homeostasis by regulating the expression of high-affinity copper uptake protein (CTR)-1 [ 73 ]. Thus, this causes the cisplatin chemoresistance to be removed by the invasive tumours that actively consume copper delivery in ATPase7A and ATPase7B to release the oncogenic enzymes and increase therapeutic efficacy [ 74 ].…”
Section: Copper and Zinc For Anti-chemoresistance In Osteosarcoma The...mentioning
confidence: 99%
“…Furthermore, increasing CTR1 expression and cytosolic Cu chaperone antioxidant protein 1 (ATOX1) levels reduced cisplatin chemoresistance [ 74 , 79 ]. Thus, the regulations of ATP7A, ATP7B, CTR1, and ATOX1 are vital and involved in the chain of cisplatin transportation [ 73 ].…”
Section: Copper and Zinc For Anti-chemoresistance In Osteosarcoma The...mentioning
confidence: 99%